Screener
Alto Neuroscience ANRO Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Alto Neuroscience’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001999480-26-000012
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Research and development | $20,294 | $9,974 |
| General and administrative | 6,844 | 5,702 |
| Total operating expenses | 27,138 | 15,676 |
| Loss from operations | (27,138) | (15,676) |
| Other income (expense): | ||
| Interest income | 1,561 | 1,827 |
| Interest expense | (545) | (598) |
| Loss on debt extinguishment | — | (681) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Alto Neuroscience's operating income?
- Alto Neuroscience (ANRO) reported operating income of -$27.14M in Q1 2026.
- How has Alto Neuroscience's operating income changed year-over-year?
- Alto Neuroscience's operating income decreased by 73.1% year-over-year, from -$15.68M to -$27.14M.
- What is the long-term trend for Alto Neuroscience's operating income?
- Over 2 years (2023 to 2025), Alto Neuroscience's operating income has grown at a 32.5% compound annual growth rate (CAGR), from -$37.81M to -$66.36M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Alto Neuroscience's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude